MarketInOut Stock Screener Log In | Sign Up
 

Filana Therapeutics Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 10/23/2026
Filana Therapeutics Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization31.85 mln
Float47.32 mln
Earnings Date11/11/2026

Piotroski F-Score

4 / 9
Borderline

Relative Strength

11 / 100
Significantly lagging

ROE

-56.27
Deeply negative

ROA

-35.49
Deeply negative

Business Description

Founded in 1998 and headquartered in Austin, Texas, Filana Therapeutics Inc. is a medical research company working to fight brain-wasting diseases. Its most advanced treatment, simufilam, is currently in a Phase 3 trial for Alzheimer's disease, while a separate early-stage tool called SavaDx aims to identify the condition using just a small blood sample. The company was previously called Cassava Sciences Inc. before adopting its current name in March 2026.

Key Fundamentals

EPS-0.86
ROE-56.27
ROIC-162
ROA-35.49
EBITDA, mln-41.17
EV / EBITDA0.98
EV / EBIT0.96

Quote Details

Last 0.6355
Change -0.0186 (-2.84%)
Open 0.644
Volume 310,456
Turnover 197,295
Average Volume 738,890

Financial Ratios

Leverage Ratio1.63
Current Ratio2.09
Price / Book0.66
Price / Tangible Book0.66
PEG Ratio1.62

Financial Strength

Piotroski F-Score 4 / 9
Short Ratio1.16
Short % of Float12.44

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -9.67% 18 / 100   
1 Month -17.77% 26 / 100   
2 Months -37.7% 13 / 100   
6 Months -60.53% 9 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Blog